Scottish Medicines Consortium recommends Eisai’s Kisplyx for advanced kidney cancer
pharmafile | November 12, 2019 | News story | Manufacturing and Production, Sales and Marketing | Eisai, Kisplyx, NHS, Sotland, pharma
Eisai’s Kisplyx (lenvatinib) has secured recommendation from the Scottish Medicines Consortium, it has been revealed, meaning that patients on the NHS in Scotland will soon be able to access the drug for the treatment of advanced kidney cancer.
Specifically, the drug is authorised in combination with everolimus for the treatment of advanced renal cell carcinoma (RCC) in adult patients who have received one prior vascular endothelial growth factor (VEGF)-targeted therapy.
In data drawn from 153 advanced RCC patients, the combo extended median progression-free survival of 14.6 months, compared to just 5.5 months with everolimus alone, while median overall survival was shown to be 25.5 months versus 15.4 months.
“This is great news for patients with advanced kidney cancer in Scotland,” commented Professor Robert Jones, Professor of Clinical Cancer Research at the University of Glasgow. “It’s particularly pleasing that the lenvatinib and everolimus combination is now available, as patients in Glasgow have been involved in the clinical trials over several years. As a result of their contribution the benefits of lenvatinib can now be extended to other Scottish patients with advanced RCC.”
Maureen Johnson, Kidney Cancer Scotland’s Health Professional, also remarked: “We are delighted that the SMC is recommending lenvatinib in combination with everolimus as a second line treatment for patients with advanced renal cell carcinoma. This news will be welcomed by patients and their families, who can be assured that NHS Scotland has access to this clinically effective combination to support their treatment.”
Scottish patients now join English and Welsh patients in accessing Kisplyx; NICE chose to recommend the drug back at the end of 2017 and it has been available in those regions since December of that year.
Matt Fellows
Related Content
Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …
“That gap between innovation and delivery was what stood out to me most”
Pharmafile chats with Camunda’s Natosha McNeal about the vital role of delivery, onboarding AI and …
Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study
People in their forties account for almost three-quarters of those who do not attend NHS …
